Date
of Report (Date of earliest event reported)
|
November
5, 2008
|
Targeted
Genetics Corporation
|
(Exact
name of registrant as specified in its
charter)
|
Washington
|
0-23930
|
91-1549568
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
1100
Olive Way, Suite 100, Seattle, Washington
|
98101
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code
|
(206)
623-7612
|
Not
Applicable
|
(Former
name or former address if changed since last
report)
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
99.1
|
Press
Release of Targeted Genetics Corporation dated November 5,
2008
|
|
|
|
|
Targeted
Genetics Corporation
|
|
|
|
|
Dated:
November 5, 2008
|
By:
|
/s/
David J. Poston
|
|
David
J. Poston
|
|
|
Vice
President Finance and
Chief
Financial Officer
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release of Targeted Genetics Corporation dated November 5,
2008
|